# **Carbon Reduction Plan**

### **Huma Therapeutics Limited**

21 June 2024

### Commitment to achieving Net Zero

Huma Therapeutics Limited is committed to achieving Net Zero emissions by 2050. Our Carbon Reduction Plan delineates our current emissions data, future targets, and strategic actions to realise our environmental goals. This document provides an overview of our baseline emissions, reduction targets, and the methodologies adhered to in our reporting process.

#### **Baseline Emissions**

Our baseline emissions have been calculated via an independent third party, reflecting our most up-to-date emissions data, which serve as our baseline emissions data. The calculations conform to the GHG Reporting Protocol corporate standard and the UK Government's Department for Business, Energy & Industrial Strategy (BEIS) team's conversion factors. Our emissions calculations are based on the Financial Control emission boundary.

Baseline Year: 2022		
Emissions	Total (tCO <sub>2</sub> e)	GHG protocol breakdown by scope
Scope 1	0**	Direct Emissions from fuel combustion in own buildings and vehicles
Scope 2	5*	Emissions from electricity and heating use in control of the company (Market-based)
Scope 3	1013	Emissions from the corporate value chain
		1. Purchased goods & services 501.7 2. Capital goods 36.4 3. Fuel-and energy-related activities 41.8 4. Upstream transportation & distribution 0.0** 5. Waste generated in operations 0.2 6. Business travel 210.0 7. Employee commuting 215.9 8. Upstream leased assets 5.1 9. Downstream transportation & distribution 0.0** 10. Processing of sold products 0.0** 11. Use of sold products 0.0** 12. End of life treatment of sold products 0.0** 13. Downstream leased assets 0.0** 14. Franchises 0.0** 15. Investments 0.0**
Total Emissions	1018	

<sup>\*</sup> Our location-based scope 2 emissions for the baseline year amounted to 39.31 tCO<sub>2</sub>e.

<sup>\*\*</sup> NA / Too small to warrant monitoring

#### **Current Emissions**

Current reporting year set as baseline year		
Emissions	Total (tCO₂e)	GHG protocol breakdown by scope
Scope 1	0**	Direct Emissions from fuel combustion in own buildings and vehicles
Scope 2	5*	Emissions from electricity and heating use in control of the company (Market-based)
Scope 3	1013	Emissions from the corporate value chain
		1. Purchased goods & services 501.7 2. Capital goods 36.4 3. Fuel-and energy-related activities 41.8 4. Upstream transportation & distribution 0.0** 5. Waste generated in operations 0.2 6. Business travel 210.0 7. Employee commuting 215.9 8. Upstream leased assets 5.1 9. Downstream transportation & distribution 0.0** 10. Processing of sold products 0.0** 11. Use of sold products 0.0** 12. End of life treatment of sold products 0.0** 13. Downstream leased assets 0.0** 14. Franchises 0.0** 15. Investments 0.0**
Total Emissions	1018	

<sup>\*</sup> Our location-based scope 2 emissions for the baseline year amounted to 39.31 tCO<sub>2</sub>e.

# **Emissions Reduction Targets**

- Huma Therapeutics Limited is dedicated to achieving Net Zero emissions by 2050.
- We project that our carbon emissions will decrease over the ten years period to  $590.44~tCO_2e$  by 2032. Representing a 42% reduction.

# **Carbon Reduction Projects**

- We are currently advancing toward setting a Science-Based Target through the Science-Based Target Initiative (SBTi) platform, which will help us align our goals with the latest climate science and ensure our efforts contribute meaningfully to global emissions reduction.
- Moreover, we have committed to full transparency by disclosing our emissions data through the Carbon Disclosure Project (CDP), enabling us to benchmark our progress and demonstrate our commitment to environmental responsibility to our stakeholders and the wider community.

<sup>\*\*</sup> NA / Too small to warrant monitoring

# **Declaration and Sign Off**

This Carbon reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and signed off by Mark Gilder.

Mark Gilder Signature -D2C9D861F2DB4C4...

DocuSigned by:

Global Head of Legal 21-Jun-2024 | 12:16 BST Huma Therapeutics Limited